

CLINICAL FEATURES OF HPV INFECTION IN WOMEN AND PREVENTIVE MEASURES

Shokirjonova Mushtariybegim Karimjon qizi

Central Asian Medical University, International Medical University,
Resident in Obstetrics and Gynecology.

Scientific Advisor: Abdukarimova Nozima Toshpulatovna PhD,

Senior Lecturer at the Department of Obstetrics, Gynecology, and Neonatology,
Central Asian Medical University.

<https://doi.org/10.5281/zenodo.23019630>

Annotation. *This thesis examines the clinical characteristics of Human Papillomavirus infection in women and the main approaches to its prevention. The clinical course of the infection may vary from an asymptomatic and transient form to persistent infection associated with pathological epithelial changes. Particular attention is given to the importance of early diagnosis, regular screening, identification of high-risk viral types, and assessment of individual risk factors.*

Modern preventive approaches, including vaccination, screening, health education, and timely clinical follow-up, are considered. A comprehensive prevention strategy combining these measures may contribute to the early detection of clinically significant changes, reduction of HPV-related complications, and preservation of women's reproductive health.

Keywords: *Human Papillomavirus infection, women, reproductive health, clinical features, high-risk HPV types, screening, vaccination, diagnosis, prevention, cervical health.*

Introduction

Human Papillomavirus infection is one of the most common viral infections affecting women of reproductive age and represents an important problem in modern gynecology. The infection is characterized by a diverse clinical course, ranging from transient and asymptomatic forms to persistent infection associated with pathological epithelial changes. The clinical manifestations depend on the viral genotype, duration of infection, immune response, and individual risk factors. In many cases, women do not experience specific symptoms, which may delay diagnosis and appropriate clinical management. The relevance of studying HPV infection is primarily associated with the potential consequences of persistent infection with high-risk viral types. Long-term viral persistence may contribute to progressive cellular abnormalities and requires appropriate clinical monitoring. At the same time, the presence of HPV infection does not necessarily indicate the development of severe disease, since many infections are transient and may be eliminated naturally by the immune system. Therefore, correct interpretation of laboratory findings and individualized clinical assessment are essential.

Relevance

Human Papillomavirus infection is one of the most common viral infections among women and may have an important impact on reproductive health. Its clinical course depends on the viral type, immune status, and individual risk factors. In many women, the infection remains asymptomatic, and they may be unaware of its presence for a prolonged period. In some cases, the infection is transient and may be eliminated by the immune system, whereas in other cases it may persist.

Aim

To assess the main clinical features of HPV infection in women and to determine the importance of modern preventive approaches for reducing the risk of HPV-related diseases.

Materials and Methods

Women of reproductive age underwent clinical and laboratory assessment. The study evaluated patients' complaints, medical history, clinical manifestations, screening findings, and laboratory results related to HPV infection. Risk factors, vaccination status, and participation in regular screening were also considered.

Human Papillomavirus infection is one of the most common viral infections affecting women of reproductive age. The clinical course of the infection depends on the viral genotype, immune status, and individual characteristics of the woman. In many cases, the infection remains asymptomatic and may be detected only during preventive screening. Some women may develop genital papillomatous or condylomatous lesions, particularly in association with low-risk viral types. High-risk viral types are of particular clinical importance because persistent infection may be associated with progressive epithelial abnormalities. Most HPV infections are transient and can be eliminated naturally by an effective immune response. However, persistent infection may develop when the immune system is unable to completely eliminate the virus. Reduced immune function can contribute to prolonged viral persistence and the development of pathological changes. Smoking is considered an important modifiable factor associated with persistent infection. Other sexually transmitted infections may also influence the local immune response and clinical course. Early sexual activity and multiple sexual partners may increase the likelihood of exposure to HPV. Nevertheless, infection can also occur in women with a single sexual partner.

The absence of clinical symptoms should not be considered evidence that HPV infection is absent. Clinical assessment should therefore include a detailed medical and reproductive history together with appropriate laboratory investigations. Early identification of persistent infection allows timely monitoring and further clinical evaluation.

Early detection of HPV infection is an important component of preventive reproductive healthcare. Since the infection frequently occurs without specific clinical manifestations, regular screening has considerable diagnostic importance. The main objective of screening is to identify clinically significant pathological changes at an early stage. The diagnostic process begins with an assessment of the woman's medical, reproductive, and sexual history. Clinical examination may help identify visible lesions and other abnormalities that require further assessment. Laboratory diagnostic methods play an important role in confirming HPV infection. Molecular testing can detect viral genetic material and may allow identification of clinically important high-risk viral types. Cytological assessment provides additional information about cellular changes that may occur during persistent infection. Screening results should be interpreted together with the patient's clinical history, previous screening results, and individual risk factors. A positive HPV test does not necessarily indicate advanced disease because many infections are transient and may resolve spontaneously. Persistent infection, however, requires appropriate clinical monitoring and follow-up. Abnormal screening findings may require additional diagnostic procedures according to established clinical recommendations. A structured diagnostic algorithm helps healthcare professionals select appropriate follow-up strategies.

Regular participation in screening programs improves the possibility of detecting pathological changes before they become clinically advanced.

Healthcare professionals should explain the purpose, benefits, and limitations of screening to patients. Combining clinical examination, molecular testing, and cytological assessment provides a comprehensive approach to HPV diagnosis.

Prevention of HPV infection is an important component of protecting women's reproductive health. Vaccination is one of the principal methods of primary prevention and aims to stimulate protective immunity against targeted HPV types. The preventive benefit of vaccination is greatest when it is administered before exposure to the virus. Vaccination is designed to prevent new infections and should not be considered a treatment for an already established infection.

Consequently, vaccinated women should continue to follow appropriate screening recommendations. Vaccination and screening represent complementary preventive measures and should be incorporated into comprehensive reproductive healthcare. Assessment of individual risk factors is also important when developing preventive strategies. Modifiable risk factors should be addressed through appropriate health education and lifestyle interventions. Smoking cessation is particularly relevant because smoking may contribute to the persistence of HPV infection and associated pathological changes. Prevention of other sexually transmitted infections is also important for maintaining reproductive health. Women should receive scientifically accurate information about HPV transmission, vaccination, screening, and follow-up. Healthcare professionals have an important role in explaining the benefits and limitations of available preventive measures. Improving health literacy can encourage participation in vaccination and screening programs. Regular medical examinations facilitate the early recognition of clinically significant abnormalities. Individualized counseling allows preventive recommendations to be adapted to the woman's clinical circumstances.

Results

The assessment demonstrated that HPV infection may occur both with clinical manifestations and in an asymptomatic form. Possible clinical manifestations include genital papillomatous or condylomatous lesions, local discomfort, and other reproductive-health-related complaints. Persistent infection with high-risk HPV types has particular clinical significance and requires appropriate screening and medical follow-up. The findings indicate that clinical examination alone is insufficient for reliable identification of HPV infection in all cases.

Therefore, laboratory diagnostics and preventive screening play an important role in early detection.

Conclusion

Since HPV infection may remain clinically silent, regular screening is important for its early detection and appropriate management. Vaccination, reduction of modifiable risk factors, health education, regular screening, and timely clinical follow-up should be considered complementary components of HPV prevention. A comprehensive preventive strategy may contribute to early identification of pathological changes and protection of women's reproductive health.

References

1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // *CA: A Cancer Journal for Clinicians*. - 2021. - Vol. 71, No. 3. - P. 209–249.
2. Arbyn M., Weiderpass E., Bruni L. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis // *The Lancet Global Health*. - 2020. - Vol. 8, No. 2. - P. 191–203.
3. Schiffman M., Doorbar J., Wentzensen N. et al. Carcinogenic human papillomavirus infection // *Nature Reviews Disease Primers*. - 2016. - Vol. 2.
4. Bosch F.X., Lorincz A., Muñoz N. et al. The causal relation between human papillomavirus and cervical cancer // *Journal of Clinical Pathology*. - 2002. - Vol. 55, No. 4. - P. 244–265.
5. Doorbar J., Egawa N., Griffin H. et al. Human papillomavirus molecular biology and disease association // *Reviews in Medical Virology*. - 2015. - Vol. 25, Suppl. 1. - P. 2–23.
6. Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer // *The Lancet*. - 2019. - Vol. 393, No. 10167. - P. 169–182.